{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:52:13Z","timestamp":1781549533233,"version":"3.54.5"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1755","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Aficamten (Myqorzo \u2013 Cytokinetics), an oral cardiac myosin inhibitor, has been approved by the FDA to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It is the second cardiac myosin inhibitor to be approved in the US for this indication; mavacamten (Camzyos) was approved in 2022.<\/jats:p>","DOI":"10.58347\/tml.2026.1755c","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:57:32Z","timestamp":1781546252000},"page":"85-87","source":"Crossref","is-referenced-by-count":0,"title":["Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,5,25]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:57:32Z","timestamp":1781546252000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1755c"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":0,"journal-issue":{"issue":"1755","published-online":{"date-parts":[[2026,5,25]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1755c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}